Literature DB >> 1634799

Association of gastric hypoacidity with opportunistic enteric infections in patients with AIDS.

P C Belitsos1, J K Greenson, J H Yardley, J R Sisler, J G Bartlett.   

Abstract

To determine the relation and possible significance of gastric hypoaciditity to chronic diarrhea in AIDS, patients with and without chronic (greater than 1 month) diarrhea underwent fasting gastric juice pH measurement and microbiologic study and upper and lower endoscopy with biopsy. All 8 patients with diarrhea and high gastric pH (greater than 3; mean, 6.1 +/- 1.0) had gastric bacterial overgrowth (greater than 10(4) bacteria/mL) along with opportunistic enteropathogens in the duodenum or rectosigmoid, but only 1 of 6 patients with diarrhea and gastric pH in the normal range (less than or equal to 3; mean, 1.9 +/- 0.7) had overgrowth or an opportunistic enteropathogen. By contrast, all but 1 of 9 controls (AIDS patients without diarrhea) had normal fasting gastric pH (mean, 2.9 +/- 1.5). Overall, the presence of gastric hypoacidity was associated with identification of opportunistic enteropathogens (P = .035). Thus, gastric hypoacidity is associated with quantitative bacterial overgrowth and opportunistic enteric infections and may be etiologically important in the pathophysiology of the chronic diarrhea seen in some AIDS patients.

Entities:  

Mesh:

Year:  1992        PMID: 1634799     DOI: 10.1093/infdis/166.2.277

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  18 in total

1.  Upper gastrointestinal endoscopy in Malawi: an opportunity.

Authors:  Will Howson
Journal:  Malawi Med J       Date:  2010-12       Impact factor: 0.875

2.  No relationship between gastric pH, small bowel bacterial colonisation, and diarrhoea in HIV-1 infected patients.

Authors:  C M Wilcox; K B Waites; P D Smith
Journal:  Gut       Date:  1999-01       Impact factor: 23.059

Review 3.  Noncommunicable diseases in HIV infection in low- and middle-income countries: gastrointestinal, hepatic, and nutritional aspects.

Authors:  Paul Kelly; Haroon Saloojee; Jennifer Y Chen; Raymond T Chung
Journal:  J Acquir Immune Defic Syndr       Date:  2014-09-01       Impact factor: 3.731

Review 4.  Small intestinal bacterial overgrowth syndrome.

Authors:  Jan Bures; Jiri Cyrany; Darina Kohoutova; Miroslav Förstl; Stanislav Rejchrt; Jaroslav Kvetina; Viktor Vorisek; Marcela Kopacova
Journal:  World J Gastroenterol       Date:  2010-06-28       Impact factor: 5.742

5.  Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study.

Authors:  J Thorens; F Froehlich; W Schwizer; E Saraga; J Bille; K Gyr; P Duroux; M Nicolet; B Pignatelli; A L Blum; J J Gonvers; M Fried
Journal:  Gut       Date:  1996-07       Impact factor: 23.059

Review 6.  Persisting diarrhoea and malabsorption.

Authors:  G C Cook
Journal:  Gut       Date:  1994-05       Impact factor: 23.059

7.  Azole resistance in oropharyngeal Candida albicans strains isolated from patients infected with human immunodeficiency virus.

Authors:  X He; R N Tiballi; L T Zarins; S F Bradley; J A Sangeorzan; C A Kauffman
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

8.  Gastric and intestinal barrier impairment in tropical enteropathy and HIV: limited impact of micronutrient supplementation during a randomised controlled trial.

Authors:  Paul Kelly; Tamara Shawa; Stayner Mwanamakondo; Rose Soko; Geoff Smith; G Robin Barclay; Ian R Sanderson
Journal:  BMC Gastroenterol       Date:  2010-07-06       Impact factor: 3.067

9.  Changes in parietal cell structure and function in HIV disease.

Authors:  G Lake-Bakaar; M Elsakr; N Hagag; S Lyubsky; J Ahuja; B Craddock; R T Steigbigel
Journal:  Dig Dis Sci       Date:  1996-07       Impact factor: 3.199

Review 10.  Dysbiotic infection in the stomach.

Authors:  Hisashi Iizasa; Shyunji Ishihara; Timmy Richardo; Yuichi Kanehiro; Hironori Yoshiyama
Journal:  World J Gastroenterol       Date:  2015-10-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.